  Cisatracurium Besylate section { margin-bottom: 20px; } table { border-collapse: collapse; } table, tr, th, td { border: 1px solid black; } th, td { padding: 0px 8px 0px 8px; text-align: left; vertical-align: top; } h3, p, ol.custom-counter, li { margin: 0px; padding: 0px; } .text-red { color: red; } .text-black { color: black; } ul.custom-dash { list-style: none; padding-left: 0; margin: 0; } ul.custom-dash > li { display: flex; align-items: flex-start; } ul.custom-dash > li::before { content: "–"; margin-right: 0.5em; flex-shrink: 0; line-height: 1; } ul.custom-dash > li > \*:not(::before) { flex: 1; } ul.custom-dash > li.no-dash::before { content: ""; width: 1em; margin-right: 0.5em; flex-shrink: 0; } /\* Change the ol style \*/ ol.custom-counter { list-style: none; padding-left: 0; counter-reset: custom calc(var(--start, 1) - 1); } ol.custom-counter li { counter-increment: custom; margin-bottom: 5px; } ol.custom-counter li::before { content: counter(custom) ") "; } /\* This is just for this file \*/ ul.custom-bullet-arrow { list-style: none; padding-left: 0; margin: 0; } ul.custom-bullet-arrow > li { display: flex; align-items: flex-start; } ul.custom-bullet-arrow > li::before { content: "↑"; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet-arrow > li.no-arrow::before { content: ""; width: 0.5em; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet\_arrow ul { list-style-type: disc; padding-left: 1.5em; margin-top: 0.5em; } img.resized-200 { width: 200px; height: auto; } img.resized-400 { width: 400px; height: auto; } img.resized-600 { width: 600px; height: auto; } .mb-10px { margin-bottom: 10px; } .mb-20px { margin-bottom: 20px; } .mt-10px { margin-top: 10px; } .mt-20px { margin-top: 20px; } .reference-notes { font-size: 11px; } .text-indent-45px { text-indent: 45px; } .text-bold { font-weight: bold; } .text-center { text-align: center; }

### Cisatracurium Besylate (Nimbex)

<table><tbody><tr><th style="width: 18%;">Class</th><td><p>Nondepolarizing Muscle Blocker (NDMB)</p><p>Intermediate acting</p><p>Isolated isomer of atracurium; unlike atracurium, it does not have a histamine release</p></td></tr><tr><th>Subclass</th><td><p>Benzylisoquinoline</p></td></tr><tr><th>Quick notes</th><td><p>Muscle relaxant of choice for patients with renal and liver failure.</p><p>Fewer side effects than atracuronium.</p><p>Cisatracurium has replaced atracuronium in the US.</p></td></tr><tr><th>Indications</th><td><p>Aid in intubation and relaxation of skeletal muscle during surgery</p></td></tr><tr><th>Action</th><td><p>Binds competitively to cholinergic receptors in motor end-plate neurons, blocking acetylcholine from accessing the receptors.</p></td></tr><tr><th>Onset</th><td><p>2 minutes</p></td></tr><tr><th>Duration</th><td><p>20-35 minutes</p></td></tr><tr><th>Elimination<br>Half-life</th><td><p>22 minutes</p></td></tr><tr><th>Dosing</th><td><p>0.2 mg/kg</p></td></tr><tr><th>Maintenance</th><td><p>0.02 mg/kg</p></td></tr><tr><th>Infusion dose</th><td><p>Around 2 mcg/kg/min, titrate to TOF</p><p>Avoid &lt; 2 years of age</p></td></tr><tr><th>Diluent for infusion</th><td><p>Avoid LR and use NSS</p><p>Atracurium degrades more rapidly in LR</p></td></tr><tr><th>Histamine release</th><td><p>No</p></td></tr><tr><th>Metabolism</th><td><p>Hoffman elimination (pH and temperature-dependent)</p></td></tr><tr><th>Metabolites</th><td><p>laudanosine and monoquaternary alcohol- no clinical effects</p></td></tr><tr><th>Pregnancy</th><td><p>B</p><p>Consider using a <b>benzyl alcohol</b>-free formulation</p><p>However, <b>benzyl alcohol</b> it is rapidly metabolized and</p><p>exposure to the fetus is unlikely.</p></td></tr><tr><th>Breast feed</th><td><p>Unlikely to reach the infant's bloodstream due to its high polarity and poor oral absorption.</p><p>Breastfeeding can likely resume once the medication's effects have worn off.</p></td></tr><tr><th>pH</th><td><p>3.25 to 3.65 (acidic)</p></td></tr><tr><th>Incompatible with</th><td><p>Alkaline solutions such as sodium bicarbonate and thiopental</p><p>ketorolac or propofol for Y-site continuous infusion</p><p>It may precipitate in a line containing an alkaline solution</p></td></tr><tr><th>Contraindications</th><td><p>Hypersensitivity to Cisatracurium or benzyl alcohol</p><p class="text-red">Peds &lt; 1 month of age and low birth-weight infants, because the formulation contains benzyl alcohol</p></td></tr><tr><th>Reversal agent</th><td><p>Neostigmine, edrophonium, or pyridostigmine with an anticholinergic agent.</p><p>Sugammadex <span class="text-red">WILL NOT</span> reverse Benzylisoquinoline NMBDs.</p></td></tr><tr><th>Elimination</th><td><p><b>Nimbex:</b> Undergoes spontaneous degradation</p><p><b>Metabolites:</b> Primarily eliminated by the kidneys and liver</p></td></tr><tr><th>Route of elimination</th><td><p>Laudanosine: 70% excreted in bile, while the remainder is excreted the urine.</p></td></tr><tr><th>Adverse reactions</th><td><p>&lt; 1% (rare)</p><p>bradycardia, hypotension, bronchospasm, rash, anaphylaxis, prolonged neuromuscular blockade, and myopathy</p></td></tr><tr><th>Vol of distribution</th><td><p>145 mL/kg, relatively small due to its relatively large molecular weight and high polarity.</p></td></tr><tr><th>Drugs that enhance Nimbex</th><td><p>Inhalation agents, local anesthetics….</p><p>See the list at the bottom of this page.</p></td></tr><tr><th>Drugs that decrease the duration</th><td><p>phenytoin or carbamazepine (anticonvulsants)</p></td></tr><tr><th>Vial strength:</th><td><p>2mg/mL</p></td></tr><tr><th>Kept refrigerated</th><td><p>Yes, at 2 to 8 °C</p><p>Do not freeze.</p><p>Protected from light to preserve potency.</p><p>The potency loss rate is as high as 5% monthly at room temperature.</p><p>Once removed from refrigeration to room temperature storage,</p><p>use within 21 days.</p></td></tr></tbody></table>

The preservative benzyl alcohol

**Note:** Benzyl alcohol is not in all vials of Cisatracurium.

Avoid administering Cisatracurium that contains the preservative in pediatric patients < 1 month of age and in low-birth-weight infants.

Adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs.

**Concomitant infusion** of Cisatracurium and pantoprazole has been shown

to produce turbidity, suggesting drug precipitation.

Avoid the simultaneous administration of those two drugs, if possible.

**Pregnancy Category: B**

May be acceptable. Either animal studies show no risk, but human studies are not available, or animal studies have shown minor risks, and human studies have been conducted and shown no risk.

Drugs that enhance Cisatracurium:

Magnesium salts

Bacitracin

Polymixin b

Calcium channel blockers

Procainamide

Clindamycin

Quinidine

Colistin quinine

Ketorolac

Sod. Colistiemethate

Lincomycin

Spironolactone

Lithium

Tetracyclines

Vancomycin

Loop diuretics

Aminoglycosides (include gentamicin, tobramycin, amikacin, neomycin, and streptomycin)

Drugs that contain ammonium compounds may trigger an allergic reaction with hairdressers.

-   A study suggests that repetitive exposure to quaternary ammonium compounds used in hairdressing is a risk factor for sensitization to certain muscle relaxants.
-   Hairdressers are routinely exposed to a wide range of hair products containing the quaternary ammonium compound.
-   This repeated exposure to quaternary ammonium compounds can lead to the development of IgE antibodies specific.
-   Cisatracurium contains a quaternary ammonium.
-   After the administration of cisatracurium, the quaternary ammonium can act as an antigenic epitope, triggering an immune response in sensitized individuals and possibly an anaphylactic reaction.
-   One study showed that 7.4% of hairdressers had IgE antibodies to quaternary ammonium, compared to only 1.6% of non-hairdressing apprentices.
-   However, this was only a study and lacks the data of hairdressers having allergic reactions from drugs that contain a quaternary ammonium.

Stoelting’s Pharmacology & Physiology in Anesthetic Practice 6th Ed, 2022

CH. 12 Neuromuscular-Blocking Drugs and Reversal Agents, pp. 315, 319

Pamela Flood, James P. Rathmell

Morgan & Mikhail’s Clinical Anesthesiology 7th Ed., 2022

CH.11, Neuromuscular Blocking Agents, p. 206, 210

Cisatracurium Besylate

Pfizer Medical (accessed 09/2025)

https://www.pfizermedical.com/cisatracurium-besylate

NIMBEX (cisatracurium besylate) injection, for intravenous use-FDA

Access Data FDA (accessed 09/2025)

https://www.accessdata.fda.gov/drugsatfda\_docs/label/2018/020551s020,s26lbl.pdf

Clinical pharmacokinetics of cisatracurium besilate

Clinical Pharmacokinetics, 1999 Jan;36(1):27-40

D F Kisor , V D Schmith

Cisatracurium

StatPearls, October 24, 2023.

Andrew D. Strawbridge; Niloufar R. Khanna; Preeti Patel; Joshua M. Hauser.

https://www.ncbi.nlm.nih.gov/books/NBK539842/

cisatracurium

DrugBank (Accessed o9/2025)

https://go.drugbank.com/drugs/DB00565

Prevalence of IgE against neuromuscular blocking agents in hairdressers and bakers

Clinical & Experimental Allergy, 2013;43:1256-1262

Dong S, Acouetey DS, Guéant-Rodriguez R-M, Zmirou-Navier D, Rémen T, Blanca M, Mertes PM, Guéant J-L